Form 4: Fate Therapeutics Executive Receives Stock Grants with Time-Based and Performance-Based Vesting

Cindy Tahl, General Counsel and Secretary of Fate Therapeutics, was granted 200,000 shares of common stock through restricted stock units with both time-based and performance-based vesting conditions.

Summary

• Cindy Tahl, the General Counsel and Secretary of Fate Therapeutics, received a grant of 200,000 shares of common stock on July 29, 2024.
• The grant is in the form of restricted stock units (RSUs).
• 100,000 of the units are subject to time-based vesting, and 100,000 are subject to performance-based vesting.
• 25,000 time-based units will vest on August 1, 2025, and 75,000 will vest on August 1, 2026, contingent on continued employment.
• The performance-based units vest based on the achievement of specific late-stage clinical and regulatory milestones by July 29, 2028.
• Half of the performance-based units will vest one year after two of the three milestones are achieved, and the remaining half will vest one year after all three milestones are achieved, also contingent on continued employment.

Sentiment

Score: 7

Explanation: The document describes a standard executive compensation practice. The inclusion of performance-based vesting is a positive sign, aligning executive interests with company goals. Overall, the sentiment is neutral to slightly positive.

Positives

• The grant of RSUs to a key executive like the General Counsel and Secretary suggests the company is incentivizing leadership.
• The performance-based vesting ties executive compensation to the achievement of critical clinical and regulatory milestones, aligning interests with shareholders.

Risks

• The performance-based vesting is contingent on achieving specific clinical and regulatory milestones by July 29, 2028; failure to achieve these milestones could result in the forfeiture of those units.
• The time-based vesting is contingent on continued employment, so if the reporting person leaves the company, they may forfeit unvested units.

Future Outlook

The vesting of the restricted stock units is dependent on continued employment and the achievement of specific clinical and regulatory milestones, indicating a focus on long-term performance and retention of key personnel.

Industry Context

Stock grants and RSU awards are common practices in the biotechnology industry to attract, retain, and incentivize key executives, aligning their interests with the company's long-term success and shareholder value.

Stakeholder Impact

• Shareholders may view the performance-based vesting as a positive incentive for management to achieve key clinical and regulatory milestones.
• Employees may see this as a positive sign of the company investing in its leadership.

Key Dates